Effect of Li+ therapy and site of origin on cerebrospinal fluid beta-amyloid precursor protein derivatives.
Clarke
N A
NA
Institute of Neurology, Queen Square, London.
Procter
A W
AW
Webster
M T
MT
Francis
P T
PT
Hodgkiss
A D
AD
Bowen
D M
DM
D000544:Alzheimer Disease / Q000134:cerebrospinal fluid; D016564:Amyloid beta-Protein Precursor / Q000134:cerebrospinal fluid*; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001284:Atrophy; D001714:Bipolar Disorder / Q000134:cerebrospinal fluid / Q000188:drug therapy; D001921:Brain / Q000473:pathology; D003866:Depressive Disorder / Q000134:cerebrospinal fluid* / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008094:Lithium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D016564:Amyloid beta-Protein Precursor; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D008094:Lithium